Journal
NATURE CHEMICAL BIOLOGY
Volume 4, Issue 8, Pages 483-490Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nchembio.96
Keywords
-
Categories
Funding
- Biotechnology and Biological Sciences Research Council [BB/F007124/1] Funding Source: Medline
- Biotechnology and Biological Sciences Research Council [BB/F007124/1] Funding Source: researchfish
- BBSRC [BB/F007124/1] Funding Source: UKRI
Ask authors/readers for more resources
Pathological hyperphosphorylation of the microtubule-associated protein tau is characteristic of Alzheimer's disease (AD) and the associated tauopathies. The reciprocal relationship between phosphorylation and O-GlcNAc modification of tau and reductions in O-GlcNAc levels on tau in AD brain offers motivation for the generation of potent and selective inhibitors that can effectively enhance O-GlcNAc in vertebrate brain. We describe the rational design and synthesis of such an inhibitor (thiamet-G, K-i = 21 nM; 1) of human O-GlcNAcase. Thiamet-G decreased phosphorylation of tau in PC-12 cells at pathologically relevant sites including Thr231 and Ser396. Thiamet-G also efficiently reduced phosphorylation of tau at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus, which reveals the rapid and dynamic relationship between O-GlcNAc and phosphorylation of tau in vivo. We anticipate that thiamet-G will find wide use in probing the functional role of O-GlcNAc in vertebrate brain, and it may also offer a route to blocking pathological hyperphosphorylation of tau in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available